Skip to main content

Table 1 Baseline characteristics of study population proof of concept phase IIa study

From: Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

Demographic data DIMS0150 (n = 22) Placebo (n = 12)
Gender Male (%) 12 (54.55) 6 (50.00)
  Female (%) 10 (45.45) 6 (50.00)
Race Caucasian 22 (100.00) 12 (100.00)
Age (years) Mean (SD) 41.3 (14.96) 39.7 (12.37)
  Min, Max 23.0, 72.0 22.0, 56.0
Other characteristics DIMS0150 (n = 22) Placebo (n = 12)
Disease duration (days) n 16 7
  Missing 6 5
  Mean (SD) 916.1 (871.85) 1760.6 (806.71)
  (Min, Max) (154.0, 3555.0) (922.0, 3003.0)
DAI score at screening n 22 12
  Missing 0 0
  Mean (SD) 7.9 (1.19) 7.9 (1.56)
  (Min, Max) 7.0, 10.0 6.0, 11.0
UC extent Beyond splenic flexure 3 (13.64%) 2 (16.67%)
  Up to splenic flexure 10 (45.45%) 6 (50.00%)
  Up to sigmoid descending junction 7 (31.82%) 3 (25.00%)
  Up to recto-sigmoid junction 1 (4.55%) 1 (8.33%)
  Not known 1 (4.55%) 0 (0.00%)
Number of subjects taking glucocorticoids medication during the study   20 (90.91%) 11 (91.67%)
Corticoids acting locally Number of steroid medications (PT) 3  
  Budenoside 2 (9.09%)  
  Prednisolone sodium phosphate 1 (4.55%)  
Glucocorticoids Number of steroid medications (PT) 21 12
  Hydrocortisone 1 (4.55%) 1 (8.33%)
  Methylprednisolone 1 (4.55%) 1 (8.33%)
  Prednisolone 19 (86.36%) 10 (83.33%)
  1. Steroids medication (PT) that occur more than once during the study period will be counted only once within a subject.
  2. Percentages calculated for the number of subjects in the safety population by treatment group.